Mass-produced compounded GLP-1 drugs bypass FDA safeguards, raising sterility, quality, and supply-chain risks—putting patients at risk despite ending shortages.
John Hertig, PharmD, MS CPPS, FASHP, FFIP
Advertisement
Articles by John Hertig, PharmD, MS CPPS, FASHP, FFIP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
Closing the Gaps in Men’s Health Through MTM and Community Engagement
5